Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro

SIMPLE SUMMARY: Systemic treatment options for advanced neuroendocrine tumors have significantly been improved in the last decade. However efficacy of systemic therapy is limited by tumor resistance and therefore there is a need for further treatment options. Inhibition of the Ras-Raf-Mek-Erk signal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xi-Feng, Spöttl, Gerald, Maurer, Julian, Nölting, Svenja, Auernhammer, Christoph Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004919/
https://www.ncbi.nlm.nih.gov/pubmed/33807122
http://dx.doi.org/10.3390/cancers13061485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004919/
https://www.ncbi.nlm.nih.gov/pubmed/33807122
http://dx.doi.org/10.3390/cancers13061485

Ejemplares similares